Advances in Interventional Oncologic Therapies
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 25 May 2024 | Viewed by 1111
Special Issue Editors
Interests: cancer therapy; treatment; arterial and venous embolization; interventional radiology; cancer biomarkers
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Interventional oncologic therapies (IOT) have become an essential part of cancer treatment, encompassing essentially all cancer types including cancer of the liver, prostate, breast, colon, lung, kidney and pancreas. It has evolved from basic biopsy of a newly found mass to diagnose a cancer to complex endovascular cancer treatment with a curative intent such as radioembolization in liver primary cancer patients. With personalized medicine and the advancement of immunotherapy in cancer treatment, interventional oncologic therapies have also progressively advanced in terms of the method of treatment, science behind each technique and availability of clinical outcome data.
In this Special Issue, “Advances in Interventional Oncologic Therapies”, we aim to collaborate and share the newest, cutting-edge research, clinical trials, and comprehensive systemic reviews including meta-analysis on some of the interventional oncologic therapies. Some of the topics we hope to include are:
- Basic and translational science research on interventional oncologic therapies
- New interventional oncologic therapies
- Cancers
(a) Liver
(b) Kidney
(c) Pancreas
(d) Lung
(e)Prostate
(f) Breast
(g) Thyroid
(h) Bone
(i) Others - Endovascular tumor treatment
(a) Radioembolization
(b) Chemoembolization
(c) Other embolic oncologic therapies - Tumor ablation
(a) Microwave ablation
(b) Cryoablation
(c) Irreversible electroporation
(d) Histotripsy
(e) HIFU
(f) RFA
(g) H-FIRE
(h) Other ablative therapies
Dr. Edward W. Lee
Dr. Dong Il Gwon
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
